Dendritic Cell Therapy (DCT) is a form of immunotherapy. Like other immunotherapeutic approaches, its goal is to support the body’s immune system in recognising structures associated with cancer cells and initiating an immune response.
Conventional immunotherapy drugs often target shared tumour markers or common genetic mutations found in certain types of cancer. However, many patients have tumours with rare or highly individualised molecular characteristics that are not addressed by standard therapies currently available on the market.
DCT offers a more personalised approach: using a patient’s own immune cells, dendritic cells are processed in our own GMP-certified laboratory and exposed to tumour - associated information derived from the patient’s own sample. This allows the development of a cell-based therapy tailored to the individual tumour profile and may provide an immunotherapeutic option also for patients with less common cancer types.
Each treatment is individualised, and potential effects depend on various factors such as tumour type, disease stage, and the patient’s immune status. We would be happy to advise you in a personal consultation.
Frank Gansauge gives an overview of the DCT process.
Dendritic Cell Therapy (DCT) is a personalised and well-tolerated form of immunotherapy that may be considered for patients with various types of cancer and across different age groups.
Discuss it with usDendritic Cell Therapy (DCT) is an advanced immunotherapy designed to help your immune system recognise features unique to your tumour.
In our certified lab, we isolate immune cells from a small blood sample and process them to generate dendritic cells exposed to tumour-specific markers. After several days, these cells are returned to your bloodstream. This approach aims to support your immune system to detect and target previously unrecognised cancer-related markers.
Consultation with Professor Gansauge in Berg. Blood is taken and a vitamin infusion is given. (approx. 2.5 hours)
In our laboratory, dendritic cells are matured after being exposed to cancer-specific markers derived from your blood sample.
The mature dendritic cells are administered through a simple injection into the skin of the abdominal area. This is typically followed by a supportive vitamin infusion. (approx. 2 hours)
Consultation with Professor Gansauge in Berg. Blood is taken and a vitamin infusion is given. (approx. 2.5 hours)
In our laboratory, dendritic cells are matured after being exposed to cancer-specific markers derived from your blood sample.
The mature dendritic cells are administered through a simple injection into the skin of the abdominal area. This is typically followed by a supportive vitamin infusion. (approx. 2 hours)
Learn about the experience had by some of our previous patients..
Meet Matt
“What works for me may not work for everyone but it did [work for me] and I’m very excited about that.”
Watch the Video
Meet Wendy
“I feel DCT has had an impact for me… the first time I came my scan showed that my cancer had shrunk and since then it’s been stable”
Watch the Video
Meet Ben
“I think [that] DCT and LDG have definitely contributed to the good result that I have had so far.”
Watch the Video
We will be back in touch with you as soon as we can.
Mon - Fri 08.00 - 12.00 CET